Acarix CADScor®System for early rule-out of Coronary Artery Disease (CAD) gains traction from established German users.


Acarix AB (publ) (“Acarix”), today reported positive feedback from German users of its handheld CADScor®System for ruling out CAD. Germany is an important market and Acarix offers a reimbursement code for private patients and is continuing the reimbursement process for statutory health insurance patients with the aim of providing physicians with more opportunities to use the CADScor®System for their patients.


About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.